- Home
- LE vs CMRX Comparison
LE vs CMRX Comparison
Compare LE & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LE
- CMRX
- Stock Information
- Founded
- LE 1963
- CMRX 2000
- Country
- LE United States
- CMRX United States
- Employees
- LE N/A
- CMRX N/A
- Industry
- LE Clothing/Shoe/Accessory Stores
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- LE Consumer Discretionary
- CMRX Health Care
- Exchange
- LE Nasdaq
- CMRX Nasdaq
- Market Cap
- LE 357.5M
- CMRX 394.1M
- IPO Year
- LE N/A
- CMRX 2013
- Fundamental
- Price
- LE $11.30
- CMRX $5.15
- Analyst Decision
- LE Strong Buy
- CMRX Strong Buy
- Analyst Count
- LE 2
- CMRX 2
- Target Price
- LE $20.00
- CMRX $8.50
- AVG Volume (30 Days)
- LE 77.9K
- CMRX 1.7M
- Earning Date
- LE 03-26-2025
- CMRX 02-27-2025
- Dividend Yield
- LE N/A
- CMRX N/A
- EPS Growth
- LE N/A
- CMRX N/A
- EPS
- LE N/A
- CMRX N/A
- Revenue
- LE $1,436,124,000.00
- CMRX $159,000.00
- Revenue This Year
- LE N/A
- CMRX N/A
- Revenue Next Year
- LE $1.97
- CMRX $1,690.28
- P/E Ratio
- LE N/A
- CMRX N/A
- Revenue Growth
- LE N/A
- CMRX N/A
- 52 Week Low
- LE $7.64
- CMRX $0.75
- 52 Week High
- LE $19.88
- CMRX $5.53
- Technical
- Relative Strength Index (RSI)
- LE 35.22
- CMRX 76.25
- Support Level
- LE $11.15
- CMRX $3.94
- Resistance Level
- LE $11.97
- CMRX $5.53
- Average True Range (ATR)
- LE 0.44
- CMRX 0.30
- MACD
- LE 0.01
- CMRX 0.07
- Stochastic Oscillator
- LE 26.98
- CMRX 78.29
About LE Lands' End Inc.
Lands' End Inc is a United States-based multi-channel retailer of casual clothing, accessories, and footwear, as well as home products. The company's operating segment includes U.S. eCommerce; International; Outfitters; Third Party and Retail. It generates maximum revenue from the U.S. eCommerce segment. The U.S. eCommerce segment offers products through the company's eCommerce website. Geographically, it derives a majority of its revenue from the United States.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.